GlassScriptPhysician profile
Lawrence B Tena
NPI 1386645695
$1,106.28
in general payments reported to CMS, 2019-2025
18 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.00 · 2021: $156 · 2022: $15.72 · 2023: $202 · 2024: $362 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.59 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $168.99 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $140.81 | 2023-2024 | |
| Daiichi Sankyo INC. | $124.08 | 2023-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $119.16 | 2021-2025 | Imfinzi, Enhertu |
| Incyte Corporation | $117.60 | 2021-2025 | Monjuvi, Jakafi, Zynyz |
| Seagen INC. | $92.99 | 2025 | |
| Janssen Biotech, INC. | $65.59 | 2024-2025 | Erleada, Rybrevant |
| Emd Serono, INC. | $46.95 | 2025 | |
| Merck Sharp & Dohme LLC | $36.27 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $36.21 | 2022-2025 | |
| Bioprotect Medical, INC. | $26.53 | 2025 | Bioprotect Balloon Implant System |
| Eisai INC. | $25.10 | 2024 | |
| Agios Pharmaceuticals, INC. | $19.60 | 2024 | Pyrukynd |
| Puma Biotechnology, INC. | $18.80 | 2023 | |
| Sobi, INC | $18.55 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $17.63 | 2023 | Vectibix, Xgeva, Nplate |
| Aveo Pharmaceuticals, INC. | $15.90 | 2024 | |
| Lilly USA, LLC | $15.52 | 2023 | Verzenio, Retevmo, Jaypirca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Tena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.